Nuvectis Pharma, Inc.
corporate_fare Company Profile
Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for NVCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for NVCT spans 10-Q, S-3, 8-K, 4.
Recent high-impact activity:
- Nuvectis Halts NXP800 in Ovarian Cancer as Q3 Loss Widens to $30.1M
- Nuvectis Q3 10-Q: $140.7M Cash, $43.1M Nine-Month Loss After Haisco Charge
- Cash Swells to $140.7M With Runway to 2H 2029 as Dual INDs Target Year-End
- NXP200 Delivers 40% ORR and Complete Responses in Recurrent Glioma at ESMO
- NXP200 Wins Breakthrough Therapy Designation in China for High-Grade Glioma
Financial Snapshot
Short Interest & Short Volume
15.16 days to coverFINRA reported short interest of 2,544,952 shares in NVCT as of the October 30, 2026 settlement, a 6.0% increase from the prior period — about 15.2 days to cover at its recent average daily volume. On November 20, 2026, 62.3% of NVCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for NVCT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-21.
Public Offering Priced · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →